Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 30 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

27%

8 trials in Phase 3/4

Results Transparency

5%

1 of 20 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
13(54.2%)
Phase 3
6(25.0%)
N/A
3(12.5%)
Phase 4
2(8.3%)
24Total
Phase 2(13)
Phase 3(6)
N/A(3)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials
NCT05304715Phase 2Completed

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Role: lead

NCT06601998Recruiting

Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

Role: lead

NCT05909683Phase 3Active Not Recruiting

Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)

Role: lead

NCT05926505Phase 2Recruiting

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

Role: lead

NCT06294600Phase 3Recruiting

Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

Role: lead

NCT06694701Phase 2Active Not Recruiting

Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)

Role: lead

NCT06608849Recruiting

The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19

Role: lead

NCT07073456Recruiting

Viscoelastic Coagulation for Early Sepsis Detection

Role: lead

NCT04990232Phase 2Completed

Personalized Immunotherapy in Sepsis

Role: lead

NCT05785442Phase 2Completed

Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia

Role: lead

NCT06141395Completed

NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification

Role: lead

NCT05897801Completed

Distinguishing Bacterial and Viral Infections by MeMed BV® Test to Limit Gut Colonization by MDRO

Role: lead

NCT04724044Phase 3Completed

Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia

Role: lead

NCT04725123Not ApplicableCompleted

Addressing Personalized Needs in Clostridioides Difficile Infection

Role: lead

NCT04357366Phase 2Completed

suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)

Role: lead

NCT05277285Phase 2Unknown

STS Administration on Coronavirus Disease (COVID-19) Patients in Critical Care

Role: lead

NCT04045743Phase 2Completed

The Benefit of Bermekimab in Patients With Systemic Sclerosis

Role: lead

NCT04680949Phase 3Completed

suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19

Role: lead

NCT04414267Phase 4Completed

Bacillus Calmette-guérin Vaccination to Prevent COVID-19

Role: lead

NCT04398004Phase 2Completed

Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early

Role: lead